IONS
SHORT CANDIDATEMeanRevComposite
23.90
Technical
0.50
Fundamental
31.70
Rank
—
Price
54.49
Hurst
0.38
As of
Aug 4, 2026
Daily
Ionis Pharmaceuticals, Inc.
HealthcareBiotechnologyIonis Pharmaceuticals is a biotechnology firm that develops and markets RNA-targeted therapies for rare genetic and neurological disorders. The company sells several approved medications including treatments for spinal muscular atrophy, hereditary angioedema, amyloidosis-related nerve damage, and ALS, among other conditions. Ionis maintains a pipeline of experimental drugs in various development stages and has partnerships with major pharmaceutical companies including Biogen, GSK, AstraZeneca, Novartis, and Roche.
Market cap
$7.2B
P/E (trailing)
—
P/E (forward)
-37.97
PEG ratio
27.33
Dividend yield
0.00%
Beta
0.38
52w range
42.08 – 86.74
Return on equity
-105.50%
Profit margin
-64.66%
Revenue growth
-40.70%
Earnings growth
—
Price history
1Y: 43.52 (-41.4%) · range 42.38–86.50
Cycle position
24/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 56 · MODERATE · exit proximity 0
Conviction
32/ 100 · maturity 0%
Buildup.334
EMA entry setup.4256
Fundamentals.2532
Volume profile
POC
44.31
Price vs POC
-1.8%
Overhead supply
94%
Runway
+1.8%
Value area 42.08–61.73 · 94% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +1.08% | +14.71% | mature |
| 40d | -20.32% | +14.71% | mature |